28 Sep 2022 , 09:29 AM
The Board of Directors authorized the appointment of Rajeev Kumar Jain as Chief Executive Officer and Key Managerial Personnel of the Company in its meeting held on September 27, 2022. He will join the company on October 3, 2022, to lead Supriya to the next stage of its growth path.
Shireesh Ambhaikar, on the other hand, has agreed to extend his services on a retainership basis for a period of two (two) years beginning October 1, 2022, where he will be designated as Technical Head for certain projects to ensure timely execution, knowledge transfer, and a smooth transition to his successor, who will join the company on October 3, 2022, said the company in its filing.
Rajeev is a seasoned expert with over 35 years of experience in manufacturing, general management, and business who has worked in prominent corporates in the API sector.
At around 9.34 AM, Supriya Lifescience was trading at Rs305.60 down by 4.93% from its previous closing of Rs321.45 on the BSE. The scrip opened at Rs310.20 and touched intraday high and low of Rs314.95 and Rs304.40 respectively.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.